Acquisition by Chen Bihua of tradable shares of MoonLake Immunotherapeuti at 72.46 subject to Rule 16b-3
| MLTX Stock | USD 41.76 0.01 0.02% |
Slightly above 62% of MoonLake Immunotherapeuti's investor base is looking to short. The analysis of the overall investor sentiment regarding MoonLake Immunotherapeutics suggests that many traders are alarmed. MoonLake Immunotherapeuti's investing sentiment can be driven by a variety of factors including economic data, MoonLake Immunotherapeuti's earnings reports, geopolitical events, and overall market trends.
MoonLake |
Filed transaction by MoonLake Immunotherapeutics 10 Percent Owner. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
MoonLake Immunotherapeuti Fundamental Analysis
We analyze MoonLake Immunotherapeuti's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MoonLake Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MoonLake Immunotherapeuti based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
MoonLake Immunotherapeuti is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
MoonLake Immunotherapeuti Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MoonLake Immunotherapeuti stock to make a market-neutral strategy. Peer analysis of MoonLake Immunotherapeuti could also be used in its relative valuation, which is a method of valuing MoonLake Immunotherapeuti by comparing valuation metrics with similar companies.
Peers
MoonLake Immunotherapeuti Related Equities
| VTYX | Ventyx Biosciences | 8.97 | ||||
| ACLX | Arcellx | 5.59 | ||||
| PLRX | Pliant Therapeutics | 5.52 | ||||
| GPCR | Structure Therapeutics | 4.08 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.80 | ||||
| TVTX | Travere Therapeutics | 3.68 | ||||
| ELVN | Enliven Therapeutics | 3.37 | ||||
| AKRO | Akero Therapeutics | 2.87 | ||||
| ABOS | Acumen Pharmaceuticals | 1.59 | ||||
| AVTE | Aerovate Therapeutics | 0.41 | ||||
| NUVL | Nuvalent | 0.09 | ||||
| CMPX | Compass Therapeutics | 0.68 | ||||
| ETNB | 89bio | 0.97 | ||||
| TERN | Terns Pharmaceuticals | 1.86 | ||||
| DAWN | Day One | 4.03 |
Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.